Filament Health plans stability program for ibogaine drug

Filament Health's new stability program

Filament Health is embarking on a stability program for its naturally derived ibogaine drug candidate, IBEX011. This initiative responds to increasing demand for Good Manufacturing Practice (GMP) quality ibogaine, standardized for clinical research, according to Rhelion Life Sciences Corp.

Background on ibogaine and its potential

Ibogaine, an alkaloid found in the root bark of the Tabernanthe iboga shrub, has been traditionally used by the Bwiti people of Gabon. Its potential therapeutic benefits, particularly for substance use disorders and conditions affecting military veterans, have gained attention in the United States. Recent developments include an Executive Order in April 2026 to accelerate treatments for serious mental illnesses, specifically mentioning ibogaine, and the donation of the University of Miami's 1994 ibogaine Investigational New Drug application to the U.S. federal government.

Regulatory and research developments

The U.S. Department of Health and Human Services has been involved in funding ibogaine research, and state-level programs are supporting clinical trials. Despite its Schedule I status in the U.S., these initiatives indicate a growing interest in exploring ibogaine's medical potential.

Why it matters

The stability program for IBEX011 is crucial as it aims to provide a reliable source of pharmaceutical-grade ibogaine for research. Filament Health's expertise in extraction and stabilization, demonstrated through its psilocybin candidate PEX010, positions it as a key player in the natural psychedelics sector. The program's success could significantly impact the availability of standardized ibogaine for clinical studies.

Filament Health's move aligns with broader trends in psychedelic research, where regulatory and funding developments are opening new avenues for exploration and potential therapeutic breakthroughs.